<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Loss-of-function defects in DNA mismatch repair (MMR), which manifest as high levels of microsatellite instability (MSI), occur in approximately 15% of <z:hpo ids='HP_0000001'>all</z:hpo> colorectal <z:mp ids='MP_0002038'>carcinomas</z:mp> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>This molecular subset of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> characterizes patients with better stage-specific prognoses who experience no benefit from <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> chemotherapy </plain></SENT>
<SENT sid="2" pm="."><plain>Most MMR-deficient (dMMR) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> are <z:hpo ids='HP_0003745'>sporadic</z:hpo>, but 15% to 20% are due to inherited predisposition (<z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>High penetrance of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> in germline MMR gene mutation carriers emphasizes the importance of accurate diagnosis of <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e> carriers </plain></SENT>
<SENT sid="4" pm="."><plain>Family-based (Amsterdam), patient/family-based (Bethesda), <z:mp ids='MP_0000002'>morphology</z:mp>-based, microsatellite-based, and IHC-based screening criteria do not individually detect <z:hpo ids='HP_0000001'>all</z:hpo> germline mutation carriers </plain></SENT>
<SENT sid="5" pm="."><plain>These limitations support the use of multiple concurrent tests and the screening of <z:hpo ids='HP_0000001'>all</z:hpo> patients with newly diagnosed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>This approach is resource intensive but would increase detection of inherited and de novo germline mutations to guide family screening </plain></SENT>
<SENT sid="7" pm="."><plain>Although <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> prognosis and prediction of <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> response are similar in both the Lynch and <z:hpo ids='HP_0003745'>sporadic</z:hpo> dMMR subgroups, these subgroups differ significantly with regard to the implications for family members </plain></SENT>
<SENT sid="8" pm="."><plain>We recommend that new <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> should be classified into <z:hpo ids='HP_0003745'>sporadic</z:hpo> MMR-proficient, <z:hpo ids='HP_0003745'>sporadic</z:hpo> dMMR, or Lynch dMMR subgroups </plain></SENT>
<SENT sid="9" pm="."><plain>The concurrent use of MSI testing, MMR protein IHC, and BRAF c.1799T&gt;A mutation analysis would detect almost <z:hpo ids='HP_0000001'>all</z:hpo> dMMR <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e>, would classify 94% of <z:hpo ids='HP_0000001'>all</z:hpo> new <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> into these MMR subgroups, and would guide secondary molecular testing of the remainder </plain></SENT>
</text></document>